Effect of Kidney or Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Somapacitan: Two Open-Label, Parallel-Group Trials.

Clin Pharmacokinet · 2021 · PMC8332591 · PMID 33754315

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an increasing trendno p-value reported

Somapacitan AUC 0–168 h showed an increasing trend with decreasing eGFR and CL Cr values, which was statistically significant when the RH group was included in the analysis.

also in 63,971 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.